CompletedNCT00240721
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolarity
This study evaluated the safety and effectiveness of topiramate for people with bipolarity.
Medication studyAges 16+
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of topiramate for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 16 years. Other eligibility criteria applied.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2000
- Recruitment status
- Completed
- Enrollment listed in the registry
- 363
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- Over 16 Years
- Official registry ID
- NCT00240721
- Official title
Show the full official title
A Randomized, Double-Blind, Multicenter, Placebo-Controlled 12-Week Study Of The Safety And Efficacy Of Two Doses Of Topiramate For The Treatment Of Acute Manic Or Mixed Episodes In Subjects With Bipolar I Disorder With An Optional Open-Label Extension
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of topiramate for people with bipolarity.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including topiramate.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 16 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...